USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $1.36, $0.23 better than the analyst estimate of $1.13. Revenue for the quarter came in at $301.5 million versus the consensus estimate of $284.54 million.
“Our operating results for the second quarter exceeded our expectations and reflect the momentum we are seeing in most of our regions. This momentum helped us generate the highest quarterly revenue and earnings per share in the Company’s history,” said Kevin Guest, Chief Executive Officer. “Although the strengthening of the U.S. dollar will be a challenge during the second half of the year, we are positioned to deliver additional sales growth as we host our International Convention in Salt Lake City, launch Celavive in China, and hold our Chinese national meeting in Macau.”
Outlook
The Company is updating its outlook for 2018 as follows:
- Consolidated net sales between $1.17 and $1.20 billion, previously between $1.13 and $1.17 billion; and
- Earnings per share between $4.75 and $5.05, previously between $4.25 and $4.55.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.